DASL-HiCap 试验 #ESMO26 @myESMO @Silke_Gillessen @ANZUPtrials @APCCC_Lugano @oncodaily @OncoAlert
🔴ADT+Darolutamide+前列腺/盆腔 RT ⬆️ MFS-CI
🟠“极高风险”的定义不同，且未纳入 PSMA/PET
🟢MFS-CI、PSA-PFS、CRPC 和后续治疗均有改善。但仍需等待最终分析和 OS！
🔵3 项研究：STAMPEDE、ENZARAD 和 DASL-HiCap。人群不同，盆腔 RT 方案不同，各项试验均有 N1 获益。
🟣结局良好，需要生物标志物
13 浏览 · 1 赞 · 0 转发 · 0 回复
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.org来源：Maite Bourlon · x.com